"Improved Treatment Of Ovarian Cancer With Nirogacestat" in Patent Application Approval Process (USPTO 20240180874).

A patent application has been filed for a new treatment for ovarian cancer using a drug called nirogacestat. This treatment specifically targets ovarian granulosa cell tumors (OvGCTs), a common subtype of ovarian cancer for which there are currently no FDA-approved therapies. The method involves orally administering 150 mg of nirogacestat twice daily to patients, with specific guidelines for managing side effects such as diarrhea, hypophosphatemia, hypokalemia, and elevated liver enzymes. The patent application provides detailed instructions for adjusting the dosage or discontinuing treatment based on the severity of these side effects. For more information, readers are encouraged to visit the full patent. [Extracted from the article]